1.Younossi ZM, Tanaka A, Eguchi Y, Lim YS, ML, Kawada N, Dan YY, Brooks-Rooney C, Negro F, Mondelli MU.
The impact of hepatitis C virus outside the liver: Evidence from Asia.Liver Int, 37(2):159-172, 2017
2.Nakazawa T, Notohara K, Tazuma S, Tanaka A, Isayama H, Tsuyuguchi T, Toshiyuki M, Takikawa H.
The 2016 diagnostic criteria for primary sclerosing cholangitis.J Gastroenterol, 52(7):838-844, 2017
3.Takahashi A, Arinaga-Hino T, Ohira H, Torimura T, Zeniya M, Abe M, Yoshizawa K, Takaki A,Suzuki Y, Kang JH, Nakamoto N, Fujisawa T, Yonemoto K, Tanaka A, Takikawa H, The Autoimmune Hepatitis Study Group, a sub group of the Intractable Hepato-Biliary Disease Study Group in Japan.
Autoimmune hepatitis in Japan: Trends in a nationwide survey.J Gastroenterol, 52(5):631-640, 2017
4.The aberrant portal hemodynamics study group supported by the ministry of health, labor and welfare of Japan
Working subgroup for clinical practice guideline for aberrant portal hemodynamics Diagnosis and treatment guidelines for aberrant portal hemodynamics (2013), Hepatol Res, 47(5):373-386, 2017
5.Tanaka A, Tazuma S, Okazaki K, Nakazawa T, Inui K, Chiba T, Takikawa H
Clinical features, treatment response, and outcome of IgG4-related sclerosing cholangitis.Clin Gastroenterol Hepatol, 15(6):920-926, 2017
6.Tanaka, A
Anti-mitochondrial autoantibodies – milestone or byway to PBC?, Ann Translational Med, 5(3):50, 2017
7.Tanaka A, Tazuma S, Nakazawa T, Isayama H, Tsuyuguchi T, Inui K, Takikawa H
No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan.J Hepatobiliary Pancreat Sci, 24(4):217-225, 2017
8.Kawashima M, Yuki H, Aiba Y, Nishida N, Kojima K, Kawai Y, Nakamura H, Tanaka A, et al.
Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population.Human Molecular Genetics, 26(3):650-659, 2017
9.Floreani A, Tanaka A, Bowlus C, Gershwin ME
Geoemidemiology and Changing mortality in primary biliary cholangitis., J Gastroenterol, 52(6):655-662, 2017
10.Canh HN, Harada K, Ouchi H, Sato Y, Tsuneyama K, Kage M, Nakano M, Yoshizawa K, Takahashi A, Abe M, Kang JH, Koike K, Inui A, Fujisawa T, Takaki A, Arinaga-Hino T, Torimura T, Suzuki Y, Fujiwara K, Zeniya M, Ohira H, Tanaka A, Takikawa H, Intractable Liver and Biliary Diseases Study Group of Japan.
Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients.J Clin Pathol, 70(11):961-969, 2017
11.Tanaka A, Leung P, Young H, Gershwin ME
Toward solving the etiological mystery of primary biliary cholangitis.Hepatology Communications, 1(4):275-287, 2017
12.Deneau M, El-Matary W, Valentino P, Abdou R, Alqoaer K, Amin A, Amir A, Auth M, Bazerbachi F, Broderick AM, Chan A, Cotter J, Doan S, El-Youssef M, Ferrari F, Furuya K, Gottrand F, Gottrand M, Gupta NA, Homan M, Kamath BM, Kim KM, Kolho KL, Konidari A, Koot B, Iorio R, Ledder O, Mack C, Martinez M, Miloh T, Mohan P, O’Cathain N, Papadopoulou A, Ricciuto A, Saubermann L, Sathya P, Shteyer E, Tanaka A, Varier RU, Venkat V, Vitola B, Vos MB, Smolka V, Woynarowski M, Yap J, Jensen MK
The natural history of primary sclerosing cholangitis in 781 children: an international, multicenter collaboration.Hepatology, 66(2):518-527, 2017
13.Tanaka A, Gershwin ME
Finding the cure for primary biliary cholangitis – Still waiting.Liver Int, 37(4):500-502, 2017
14.Okamura T, Yamamoto T, Kimura S, Miki A, Abe K, Kita H
Impact of lubiprostone on gastric emptying profile and the possible effect of concomitant domperidone in healthy adults, Int J Clin Pharmacol Ther, 55(11):861-865, 2017
15.Miki A, Yamamoto T, Maruyama K, Nakamura N, Aoyagi H, Isono A, Kita H
Extensive gastric mucosal atrophy is a possible predictor of clinical effectiveness of acotiamide in patients with functional dyspepsia, Int J Clin Pharmacol Ther, 55(12):901-904, 2017
16.Yamamoto T, Osumi S, Yanagisawa D, Yamato H, Aoyagi H, Isono A, Abe K, Kita H
Possible effect of concomitant prokinetics and herbal medicines against nausea in patients taking lubiprostone, BioMed Res Int, Article ID 3762179, 2017
17.Abe K, Nakamura N, Isono A, Toyota H, Arai H, Saito K
Inflammatory bowel disease in an elderly woman after nivolumab administration, Am J Gastroenterol, 112(11):1636-1636, 2017
18.田中 篤、滝川 一
硬化性胆管炎の診療の進歩, 医学のあゆみ, 261, 113-118, 2017
19.滝川 一
PBCの病名変更―「肝硬変」から「胆管炎」へ, 日医雑誌, 146, 83, 2017
20.滝川 一
C型肝炎治療の進歩, Keynote R・A, 5:45-48, 2017
21.滝川 一
特集:自己免疫性肝・胆道疾患のupdate。わが国の自己免疫性肝・胆道疾患診療のこれまでと将来に向けて, 肝胆膵, 74:845-846, 2017
22.滝川 一
特集;硬化性胆管炎の診療における最近の進歩。硬化性胆管炎診療の歴史的変遷, 胆と膵, 38:535-539, 2017
23.滝川 一
C型肝炎治療ガイドラインについて, 日薬誌, 69:957-960, 2017
24.滝川 一
Current Topics 「C型肝炎治療ガイドライン(第5.1版)公表, Prog.Med, 36:1592-1593, 2017
25.田中 篤
School of AutoImmune Diseases (SAIL) レポート, 肝臓, 58(3):135-136, 2017
26.田中 篤、乾あやの
小児期に発症する肝・胆道疾患 ~肝臓専門医への円滑なトランジションを~, 肝臓, 58(3):168-169, 2017
27.田中 篤
自己免疫性肝炎と原発性胆汁性胆管炎, Modern Physician, 37(3):259-264, 2017
28.田中 篤
PBCの病名変更 -「肝硬変」から「胆管炎」へ-, Medical Practice, 34:506-507, 2017
29.田中 篤、滝川 一
差分解説-C型肝炎患者におけるHBV再活性化, 日本医事新報, 4852:52, 2017
30.田中 篤
日本肝臓学会B型肝炎治療ガイドラインUpdate, Medical Practice, 34:728-735, 2017
31.田中 篤、滝川 一
差分解説-C型肝炎患者におけるHBV再活性化, 日本医事新報, 4855:48, 2017
32.田中 篤
日本肝臓学会B型肝炎治療ガイドライン Update, Medical Practice, 34(5):728-735, 2017
33.田中 篤
原発性胆汁性胆管炎, 臨床と研究, 94(5):47-51, 2017
34.田中 篤
薬物性肝障害, 内科, 119(6):1145-1149, 2017
35.田中 篤
PBCにおける自覚症状 -「無症候性」をめぐって-, 肝胆膵, 74(6):917-923, 2017
36.田中 篤
胆汁うっ滞性肝障害(PBC、PSC)における肝移植とその適応, 消化器・肝臓内科, 1(5):529-533, 2017
37.田中 篤
原発性硬化性胆管炎の予後予測因子としての血清ALP値, 胆と膵, 38(6):583-586, 2017
38.田中 篤
原発性硬化性胆管炎の診断と治療, Medican Practice, 34(7):1133-1137, 2017
39.田中 篤、滝川 一
PBCの病名変更 - 「肝硬変」から「胆管炎」へ, 消化器・肝臓内科, 1(6):620-622, 2017
40.田中 篤
原発性胆汁性胆管炎の診断と治療, 消化器・肝臓内科, 1(6):644-650, 2017
41.田中 篤
我が国におけるC型肝炎治療ガイドライン, 最新医学, 72(9):1235-1242, 2017
42.田中 篤
日本肝臓学会『C型肝炎治療ガイドライン』における治療推奨, 医学のあゆみ, 262(14):1381-1386, 2017
43.田中 篤
50の未解決課題‐B型肝炎の完全制御, Medical Tribune, 16, 2017
44.山本貴嗣
抗血栓薬による上部消化管粘膜傷害, 医事新報, 72(6):35-41, 2017
45.山本貴嗣
抗血栓療法による消化管傷害, 成人病と生活習慣病, 47(5):559-563, 2017
46.山本貴嗣
便秘症の診断と治療について-便秘型過敏性腸症候群を含めて-, 茅ヶ崎医師会報, 107:21-22, 2017
47.山本貴嗣
炎症性腸疾患の病態と治療, 東京内科医会雑誌, 33(2):199-201, 2017
48.松田圭二, 八木貴博, 塚 充雄, 赤羽拓弥, 堀内 敦, 島田 竜, 端山 軍, 岡本耕一, 土屋剛史, 野澤慶次郎, 藤井正一, 青柳 仁, 磯野朱里, 阿部浩一郎, 山本貴嗣, 喜多宏人, 笹島ゆう子, 近藤福雄, 橋口陽二郎
潰瘍性大腸炎術後回腸嚢炎の発症頻度およびリスク因子の検討, 帝京医学雑誌, 40(5):223-229, 2017
49.Uetake H, Sugihara K, Muto K, Sunaya T, Horiuchi-Yamamoto Y, Takikawa H
Clinical features of regorafenib-induced liver injury in Japanese patients from postmarketing experience, Clin Colorect Cancer, 17, e49-e58, 2018
50.Mochida S, Nakayama N, Ido A, Inoue K, Genda T, Takikawa Y, Sakaida I, Terai S, Yokosuka O,Shimizu M, Takikawa, H
Proposed Diagnostic Criteria for Acute-On-Chronic Liver Failure in Japan, Hepatol Res, 48:219-224, 2018
51.Sogo T, Takahashi A, Inui A, Fujisawa T, Ohira H, Takikawa H; Japan AIH Study Group (JAIHSG)
Clinical features of pediatric autoimmune hepatitis in Japan: a nationwide survey, Hepatol Res, 48:286-294, 2018
52.Nakayama N, Uemura H, Uchida Y, Tomiya T, Ido A, Inoue K, Genda T, Takikawa Y, Sakaida I, Terai S, Yokosuka O, Shimizu M, Takikawa H, Mochida S
A Multicenter Pilot Survey to Clarify the Clinical Features of Patients with Acute-On-Chronic Liver Failure in Japan, Hepatol Res, 48:303-312, 2018
53.Tanaka A, Gershwin ME
Therapeutic and immunological interventions in primary biliary cholangitis: from mouse models to humans. , Archives of Medical Science, 14(4):930-940, 2018
54.Suzuki Y, Mori T, Yokoyama M, Kim S, Momose H, Matsuki R, Kogure M, Nakazato T, Abe N, Isayama H, Nakazawa T, Notohara K, Tanaka A, Tsuyuguchi T, Tazuma S, Takikawa H, Sugiyama M.
A proposed severity classification system for hepatolithiasis based on an analysis of prognostic factors in a Japanese patient cohort: Implication to update clinical guideline(s) for gallstone diseases., J Gastroenterol, 53(7):854-860, 2018
55.Tanaka A, Gershwin ME.
Environmental Basis of Autoimmunity., Exp Biol Med (Maywood), 243(2):184-189, 2018
56.Tanaka A.
Is HBV-associated intrahepatic cholangiocarcinoma preventable with antiviral treatment?, Clin Gastroenterol Hepatol, 16(6):821-822, 2018
57.Natsume M, Watanabe K, Matumoto S, Naruge D, Hayashi K, Furuse J, Kawamura M, Jinno H, Sano K, Fukushima R, Aruga E, Hashiguchi Y, Tanaka A, Takikawa H, Eguchi K, Seki N.
Factors influencing cancer patients’ choice of palliative care place., J Palliative Medicine, 21(6):751-765, 2018
58.Zobair M. Younossi, Tanaka A, Eguchi Y, L Henry, Beckerman R, Mizokami M.
Treatment of Hepatitis C Virus Leads to Economic Gain Related to Reduction in Cases of Hepatocellular Carcinoma (HCC) and Decompensated Cirrhosis in Japan., J Viral Hepat, in press, 2018
59.Takahashi A, Arinaga-Hino T, Ohira H, Abe K, Torimura T, Zeniya M, Abe M, Yoshizawa K, Takaki A, Suzuki Y, Kang JH, Nakamoto N, Fujisawa T, Tanaka A, Takikawa H, Japan AIH Study Group (JAIHSG).
Nonalcoholic fatty liver disease in patients with autoimmune hepatitis., JGH open, in press, 2018
60.Tanaka A, Hirohara J, Nakano T, Yagi M, Namisaki T, Yoshiji H, Nakanuma Y, Takikawa H;
Japan PBC Study Group (JPBCSG).
Effect of deferred or no treatment with ursodeoxycholic acid in patients with early primary biliary cholangitis., Hepatol Res, in press, 2018
61.Joshita S, Yoshizawa K, Umemura T, Ohira H, Takahashi A, Harada K, Hiep CN, Tsuneyama K, Kage M, Nakano M, Kan JH, Koike K, Zeniya M, Takaki A, Torimura T, Abe M, Yokosuka O, Tanaka A, Takikawa H, the Japan Autoimmune Hepatitis Study Group (JAIHG).
Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey., J Gastroenterol, in press, 2018
62.Ikeda H, Watanabe T, Matsumoto N, Hiraishi1 T, Nakano N, Noguchi Y, Hattori N, Shigefuku R, Matsunaga K, Ishii T, Okuse C, Yotsuyanagi H, Tanaka A, Suzuki M and Itoh F.
Treatment with Daclatasvir and Asunaprevir for 24 weeks improves health-related quality of life in Japanese patients infected with hepatitis C virus., JGH open, in press, 2018
63.Yagi M, Tanaka A, Namisaki T, Takahashi A, Abe M, Honda A, Matsuzaki Y, Ohira H, Yoshiji H,Takikawa H; Japan PBC Study Group (JPBCSG).
Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study., J Gastroenterol, in press, 2018
64.Nishida N, Aiba Y, Hitomi Y, Kawashima M, Kojima K, Kawai Y, Ueno K, Nakamura H, Yamashiki N, Tanaka T, Tamura S, Mori A, Yagi S, Soejima Y, Yoshizumi T, Takatsuki M, Tanaka A, Harada K, Shimoda S, Komori A, Eguchi S, Maehara Y, Uemoto S, Kokudo N, Nagasaki M, TokunagaK, Nakamura M.
NELFCD and CTSZ loci are associated with jaundice-stage progression in primary biliary cholangitis in the Japanese population., Sci Rep, in press, 2018
65.Tanaka A
Gamma glutamyltransferase reduction leads to favorable long-term outcomes in pediatric primary sclerosing cholangitis., Hepatol Commun, in press, 2018
66.Tanaka A, Leung PSC, Gershwin ME.Pathogen infections and primary biliary cholangitis., Clinical and Experimental Immunology, in press, 2018
67.Kodashima S, Tanaka K, Matsuda K, et al
First progress report on the Japan Endoscopy Database project, Dig Endosc, 30(1):20-28, 2018
68.松田圭二, 岡田有加, 大野航平, 八木貴博, 塚本充雄, 赤羽根拓弥, 堀内 敦, 島田 竜, 端山 軍, 岡本耕一, 土屋剛史, 野澤慶次郎, 青柳 仁, 磯野朱里, 阿部浩一郎, 山本貴嗣, 喜多宏人, 笹島ゆう子, 近藤福雄, 橋口陽二郎
潰瘍性大腸炎の外科治療(Colitis associated cancer以外), 消化器・肝臓内科, 3(1):34-41, 2018
69.持田 智、中山伸朗、井戸章雄、井上和明、玄田拓哉、滝川康裕、坂井田功、寺井崇二、横須賀收、清水雅仁、滝川 一
わが国におけるAcute-On-Chronic Liver Failure (ACLF)の診断基準(案), 肝臓, 59:155-161, 2018
70.滝川 一
新薬紹介:抗ウイルス化学療法薬 グラカプレビル水和物・ピブレンタスビル配合薬, 日医誌, 146:2276-2277, 2018
71.田中 篤
日本肝臓学会B型肝炎治療ガイドラインupdate, Mebio, 35(1):39-45, 2018
72.田中 篤
肝癌の主な病因とその治療 原発性胆汁性胆管炎, 日本臨床, 76(2):310-314, 2018
73.山本貴嗣
便秘における漢方薬の使い方, レジデント, 11(1):22-30, 2018
74.山本貴嗣
薬剤性消化管傷害の現状と課題, Medical Practice, 35(1):67-70, 2018
75.山本貴嗣
高齢者の便秘, 臨床消化器内科, 33(4):1-6, 2018